Syndax is focused on the development of two potential best in class assets: entinostat and SNDX-6352.

We are developing entinostat, our small molecule Class 1 specific histone deacetylase inhibitor, in a number of clinical trials evaluating combination therapies across multiple cancer indications. Entinostat has several properties that differentiate it among HDAC inhibitors, including selectivity for Class 1 HDAC enzymes, oral once weekly delivery, safe and synergistic activity with several classes of therapeutic agents, including immune checkpoint inhibitors, and an ability to re-sensitize cancer cells to therapy.

SNDX-6352, our second asset which recently commenced first-in-human studies, is a high affinity antibody directed against a cell surface protein called Colony Stimulating Factor-1 Receptor. CSF-1R regulates a variety of critical cellular processes for macrophages and blocking CSF-1R has been shown to lead to the depletion of cells known as Tumor Associated Macrophages, or TAMS. TAMs are immunosuppressive cells found in the tumor micro-environment that can inhibit the ability of Tumor Infiltrating Lymphocytes (TILs) to attack and kill tumor cells.

Our assets, both in combination with other agents and each other, demonstrate the potential to increase the immune system’s response to cancer treatment.

CSF-1R = colony-stimulating factor receptor 1; CTL = cytotoxic T lymphocyte; HR = hormone receptor;
Ig = immunoglobulin; MDSC = myeloid-derived suppressor cell; TAM = tumor-associated macrophage; Treg = regulatory T cell